Transplantation versus novel therapies in high-risk chronic lymphoblastic leukemia (CLL)?
Precision medicine and mutation detection advances in CLL
The 2016 International Workshop of the German CLL Study Group (GCLLSG)
Panel discussion on novel therapies and targets for lymphoma
John Gribben et al.
Follow-up results of looking at treatment with ibrutinib on CLL patient survival and adverse events